Number of transplanted participants · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful stem cell collection · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor leads to higher successful stem cell collection compared with placebo (high certainty).
1 finding from 1 review
Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).
1 finding from 1 review
Overall survival ‐ not measured · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
All‐cause mortality · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
Fatigue · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
Adverse events (serious and nonserious) Medical Dictionary for Regulatory Activities (MedDRA) · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab showed no clear difference in adverse events (serious and nonserious) Medical Dictionary for… compared with placebo (low certainty).
1 finding from 1 review
Transfusion independence · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab probably leads to higher transfusion independence compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to any reason · patients with paroxysmal nocturnal hemoglobinuria
Eculizumab probably leads to lower withdrawal for any reason compared with placebo (moderate certainty).
1 finding from 1 review